Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5158039?pdf=render |
id |
doaj-756e8385780b492bb10a542c03444926 |
---|---|
record_format |
Article |
spelling |
doaj-756e8385780b492bb10a542c034449262020-11-25T02:47:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016821610.1371/journal.pone.0168216Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.Claudia Della CorteGuido CarpinoRita De VitoCristiano De StefanisAnna AlisiStefano CianfaraniDiletta OveriAntonella MoscaLaura StronatiSalvatore CucchiaraMassimiliano RaponiEugenio GaudioChristopher D ByrneValerio NobiliThere are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.http://europepmc.org/articles/PMC5158039?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Della Corte Guido Carpino Rita De Vito Cristiano De Stefanis Anna Alisi Stefano Cianfarani Diletta Overi Antonella Mosca Laura Stronati Salvatore Cucchiara Massimiliano Raponi Eugenio Gaudio Christopher D Byrne Valerio Nobili |
spellingShingle |
Claudia Della Corte Guido Carpino Rita De Vito Cristiano De Stefanis Anna Alisi Stefano Cianfarani Diletta Overi Antonella Mosca Laura Stronati Salvatore Cucchiara Massimiliano Raponi Eugenio Gaudio Christopher D Byrne Valerio Nobili Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE |
author_facet |
Claudia Della Corte Guido Carpino Rita De Vito Cristiano De Stefanis Anna Alisi Stefano Cianfarani Diletta Overi Antonella Mosca Laura Stronati Salvatore Cucchiara Massimiliano Raponi Eugenio Gaudio Christopher D Byrne Valerio Nobili |
author_sort |
Claudia Della Corte |
title |
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. |
title_short |
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. |
title_full |
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. |
title_fullStr |
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. |
title_full_unstemmed |
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. |
title_sort |
docosahexanoic acid plus vitamin d treatment improves features of nafld in children with serum vitamin d deficiency: results from a single centre trial. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment. |
url |
http://europepmc.org/articles/PMC5158039?pdf=render |
work_keys_str_mv |
AT claudiadellacorte docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT guidocarpino docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT ritadevito docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT cristianodestefanis docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT annaalisi docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT stefanocianfarani docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT dilettaoveri docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT antonellamosca docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT laurastronati docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT salvatorecucchiara docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT massimilianoraponi docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT eugeniogaudio docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT christopherdbyrne docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial AT valerionobili docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial |
_version_ |
1724751849848832000 |